`571.272.7822
`
`
`
`
`
`
` Paper No. 14
`
` Entered: June 3, 2016
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`NEPTUNE GENERICS, LLC,
`Petitioner,
`
`v.
`
`ELI LILLY & COMPANY
`Patent Owner.
`____________
`
`Case IPR2016-00240
`Patent 7,772,209 B2
`____________
`
`
`Before MICHAEL P. TIERNEY, JACQUELINE WRIGHT BONILLA, and
`TINA E. HULSE, Administrative Patent Judges.
`
`TIERNEY, Administrative Patent Judge.
`
`
`DECISION
`Institution of Inter Partes Review
`37 C.F.R. § 42.108
`
`
`
`
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`I.
`INTRODUCTION
`Neptune Generics, LLC (“Petitioner”), filed a Petition requesting an
`
`inter partes review of claims 1–22 of U.S. Patent 7,772,209 B2 (Ex. 1001,
`“the ’209 patent”). Paper 1 (“Pet.”). Patent Owner, Eli Lilly & Company,
`(“Patent Owner”) timely filed a Preliminary Response (Paper 9, “Prelim.
`Resp.”) to the Petition. We have jurisdiction under 35 U.S.C. § 314.
`To institute an inter partes review, we must determine that the
`
`information presented in the Petition shows “a reasonable likelihood that the
`petitioner would prevail with respect to at least 1 of the claims challenged in
`the petition.” 35 U.S.C. § 314(a). For the reasons set forth below, upon
`considering the Petition and the Preliminary Response, we conclude that the
`information presented in the Petition establishes a reasonable likelihood that
`Petitioner will prevail in challenging claims 1–22 of the ’209 patent. We
`authorize an inter partes review to be instituted as to those claims.
`
`Our factual findings and conclusions at this stage of the proceeding are
`based on the evidentiary record developed thus far. This decision to institute
`trial is not a final decision as to patentability of claims for which inter partes
`review is instituted. Our final decision will be based on the full record
`developed during trial.
`
`
`2
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`A. Related Proceedings
`The ’209 patent is the subject of litigation in the Southern District of
`Indiana, including Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., et al.,
`Case No. 1:10-cv-1376. Pet. 2–3, Prelim. Resp. 2.
`Additionally, Petitioner notes that the ’209 patent also was challenged
`in IPR2013-00356 by Accord Healthcare, Inc. Pet. 2.1
`The ’209 patent has also been challenged in IPR2016-00237 by
`Petitioner, and in IPR2016-00318 by Sandoz Inc.
`
`B. The ’209 Patent
`The ’209 patent claims priority benefit of a series of applications, the
`earliest of which was filed on June 30, 2000. Ex. 1001, 1:2–10.
`“As cancer cells actively proliferate, they require large quantities of
`DNA and RNA.” Declaration of W. Archie Bleyer, Ex. 1024 ¶ 67.
`Antifolates are a well-studied class of antineoplastic agents that inhibit one
`or several key folate-requiring enzymes of the thymidine and purine
`biosynthetic pathways. Ex. 1001, 1:36–41. As antifolates interfere with
`DNA and RNA synthesis, antifolates are used as chemotherapeutic drugs to
`treat certain types of cancer. Ex. 1024 ¶ 67.
`A limitation on the use of antifolate drugs is “that the cytotoxic
`activity and subsequent effectiveness of the antifolates may be associated
`with substantial toxicity for some patients.” Ex. 1001, 1:62–64.
`Homocysteine levels have been shown to be a predictor of cytotoxic events
`
`
`1 The Board declined to institute in IPR2013-00356, holding that the petition
`was not filed within the time limit imposed by 35 U.S.C. § 315(b). Accord
`Healthcare, Inc., USA v. Eli Lilly and Co., Case IPR2013-00356, slip op. 4
`(PTAB Oct. 1, 2013) (Paper 13).
`
`3
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`related to the use of certain antifolate enzyme inhibitors. Id. at 2:16–26.
`The ’209 patent states that folic acid has been shown to lower homocysteine
`levels. Id. Additionally, the patent states that it was known in the art to treat
`and prevent cardiovascular disease with a combination of folic acid and
`vitamin B12. Id. at 2:50–54.
`The ’209 patent describes “[a] method of administering an antifolate
`to a mammal in need thereof.” Ex. 1001, abstract. The method is said to
`improve the therapeutic utility of antifolate drugs by administering a
`methylmalonic acid (“MMA”) lowering agent, such as vitamin B12, to the
`host undergoing treatment. Id. at 2: 37–46. The ’209 patent also states that
`a combination of a MMA lowering agent, such as B12, and folic acid
`“synergistically reduces the toxic events associated with the administration
`of antifolate drugs.” Id. at 2:47–50
`The term antifolate is said to encompass chemical compounds that
`inhibit at least one key folate-requiring enzyme of the thymidine or purine
`biosynthetic pathways. Id. at 4:28–34. Pemetrexed disodium is the most
`preferred antifolate for the ’209 patent. Id. at 4:28–43. Pemetrexed is also
`referred to in the art as the “multitargeted antifolate” (“MTA”). Ex. 1022,
`129, Abstract 620P.
`
`C. Illustrative Claims
`The ’209 patent contains twenty-two claims, all of which are
`challenged by Petitioner. Independent claim 1 is directed to a method for
`administering pemetrexed disodium to a patient in need thereof, where folic
`acid and a MMA lowering agent, such as B12, is administered, followed by
`administering an effective amount of the pemetrexed disodium. Independent
`claim 12 is written in a Jepson claim format, where the preamble defines the
`
`4
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`admitted prior art as administering pemetrexed disodium to a patient in need
`of a chemotherapeutic treatment. Independent claim 12 further recites
`specific dosage amounts of folic acid and vitamin B12 that are administered
`to the patient prior to the first administration of the pemetrexed disodium.
`Dependent claim 2 requires the MMA lowering agent of claim 1 to be
`vitamin B12 and the remaining dependent claims recite various dosages of
`folic acid and B12, and times for administering folic acid. Certain claims
`also require the administration of cisplatin to the patient.
`Claims 1 and 12 are illustrative of the challenged claims and are
`reproduced below:
`
`1. A method for administering pemetrexed disodium to a patient
`in need thereof comprising administering an effective amount
`of folic acid and an effective amount of a methylmalonic acid
`lowering agent followed by administering an effective
`amount of pemetrexed disodium, wherein
`the methylmalonic acid lowering agent is selected from
`the group consisting of vitamin B12, hydroxycobalamin,
`cyano-10-chlorocobalamin,
`aquocobalamin
`perchlorate,
`aquo-10-cobalamin perchlorate, azidocobalamin, cobalamin,
`cyanocobalamin, or chlorocobalamin.
`
`for administering pemetrexed
`improved method
`12. An
`disodium to a patient in need of chemotherapeutic treatment,
`wherein the improvement comprises:
`a) administration of between about 350 μg and about 1000
`μg of folic acid prior to the first administration of pemetrexed
`disodium;
`b) administration of about 500 μg to about 1500 μg of
`vitamin B12, prior to the first administration of pemetrexed
`disodium; and
`c) administration of pemetrexed disodium.
`
`
`
`
`5
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`D. Prior Art Relied Upon
`
`In the ground challenging the claims, Petitioner relies on the
`following prior art:
`Rusthoven et al., Multitargeted Antifolate LY231514 as First- Line
`Chemotherapy for Patients with Advanced Non-Small-Cell Lung Cancer: A
`Phase II Study, Journal of Clinical Oncology, Vol. 17, No. 4, (April 1999),
`pp. 1194-1199 (“Rusthoven”) (Ex. 1011)
`
`European Patent Application No. 0,595,005 A1 (“EP 005”) (Ex. 1010)
`
`
`
`Petitioner also points us to the following prior art:
`
`U.S. Patent No. 5,344,932 to Edward C Taylor, issued on Sep. 6, 1994
`(“Taylor”) (Ex. 1003)
`
`Worzalla et al., Role of Folic Acid in Modulating the Toxicity and Efficacy of
`the Multitargeted Antifolate, LY231514, Anticancer Research 18:3235-3240
`(1998) (“Worzalla”) (Ex. 1005)
`
`U.S. Patent No. 4,140,707 to Cleare et al., issued on Feb. 20, 1979
`(“Cleare”) (Ex. 1006)
`
`Tsao CS, Influence of Cobalamin on the Survival of Mice Bearing Ascites
`Tumor, Pathobiology 1993; 61:104-108 (“Tsao”) (Ex. 1007)
`
`Niyikiza et al., MTA (LY231514): Relationship of vitamin metabolite profile,
`drug exposure, and other patient characteristics to toxicity, Annals of
`Oncology, Vol. 9, Suppl. 4, 1998, Abstract 609P, pg. 126 (“Niyikiza”) (Ex.
`1008)
`
`Refsum H & Ueland PM, Clinical significance of pharmacological
`modulation of homocysteine metabolism, Trends in Pharmacol. Sci., Vol. 11,
`No. 10, 1990, pp. 411-416 (“Refsum”) (Ex. 1012)
`
`Calvert AH & Walling JM, Clinical studies with MTA, British Journal of
`Cancer (1998) 78 (Suppl. 3), 35-40 (“Calvert 1998”) (Ex. 1013)
`
`
`6
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`Calvert H, An Overview of Folate Metabolism: Features Relevant to the
`Action and Toxicities of Antifolate Anticancer Agents, Seminars in
`Oncology, Vol. 26, No. 2, Suppl 6 (April), 1999, pp. 3-10 (“Calvert 1999”)
`(Ex. 1014)
`
`O’Dwyer et al., Overview of Phase II Trials of MTA in Tumors, Seminars in
`Oncology, Vol. 26, No. 2, Suppl 6 (April), 1999, pp. 99-104 (“O’Dwyer”)
`(Ex. 1015)
`
`Zervos et al., Functional folate status as a prognostic indicator of toxicity in
`clinical trials of the multitargeted antifolate LY231514, Proceedings of
`ASCO, Vol. 16, 1997, pg. 256a (“Zervos”) (Ex. 1016)
`
`Allen et al., Diagnosis of Cobalamin Deficiency I: Usefulness of Serum
`Methylmalonic Acid and Total Homocysteine Concentrations, American
`Journal of Hematology, 34, 1990, 90-98 (“Allen”) (Ex. 1017)
`
`Savage et al., Sensitivity of Serum Methylmalonic Acid and Total
`Homocysteine Determinations for Diagnosing Cobalamin and Folate
`Deficiencies, The American Journal of Medicine, 96: 1994, 239-246
`(“Savage”) (Ex. 1018)
`
`Brönstrup et al., Effects of folic acid and combinations of folic acid and
`vitamin B-12 on plasma homocysteine concentrations in healthy, young
`women, Am. J. Clin. Nutr. Vol. 68, 1998, 1104-10 (“Bronstrup”) (Ex. 1019)
`
`Carrasco et al., Acute megaloblastic anemia: homocysteine levels are useful
`for diagnosis and follow-up, Haematologica, Vol. 84(8), August 1999, 767-
`768 (“Carrasco”) (Ex. 1020)
`
`Thödtmann et al., Phase I study of different sequences of MTA (LY231514)
`in combination with cisplatin in patients with solid tumours, Annals of
`Oncology, Vol. 9, Suppl. 4, 1998, Abstract 618P, pg. 129 (“Thodtmann”)
`(Ex. 1021)
`
`Hammond et al., A Phase I and pharmacokinetic (PK) study of the
`multitargeted antifolate (MTA, LY231514) with folic acid (FA), Annals of
`Oncology, Vol. 9, Suppl. 4, 1998, Abstract 620P, pg. 129 (“Hammond”)
`(Ex. 1022)
`
`7
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`
`Morgan et al., The Effect of Folic Acid Supplementation on the Toxicity of
`Low-Dose Methotrexate in Patients with Rheumatoid Arthritis, Arthritis and
`Rheumatism, Vol. 33, No. 1, January 1990, pp. 9-18 (“Morgan”) (Ex. 1023)
`
`
`Petitioner contends that the challenged claims are unpatentable under
`35 U.S.C. § 103 based on the following ground (Pet. 15–48):
`References
`Basis
`Claims challenged
`
`Rusthoven in view of EP 005
`
`§ 103
`
`1–22
`
`
`
`Level of Ordinary Skill in the Art
`E.
`Petitioner’s declarant, Dr. W. Archie Bleyer, testifies that, a
`person of ordinary skill in connection with the ’209 patent would have
`had an M.D. degree with significant experience in treating cancer
`patients, including an understanding of antineoplastic agents, such as
`antifolates and their efficacies, safety, adverse effects, toxicities, etc.
`Ex. 1024 ¶ 20. Additionally, Dr. Bleyer testifies that a person of
`ordinary skill in the art may work as part of a multi-disciplinary team.
`Id. at ¶ 21. At this stage of the proceeding, Patent Owner does not
`dispute this recitation of the level of ordinary skill in the art. We
`adopt the level of ordinary skill in the art identified by Dr. Bleyer, as
`it is consistent with the prior art of record. See Okajima v. Bourdeau,
`261 F.3d 1350, 1355 (Fed. Cir. 2001) (the prior art itself can reflect
`the appropriate level of ordinary skill in the art).
`
`
`8
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`
`II.
`PRIOR LITIGATION
`
`Patent Owner does not address the merits of the Petition, but contends
`that the Petition should be denied because a district court has already
`considered and rejected similar arguments in its decision on validity of
`claims 9, 10, 12, 14, 15, 18, 19, and 21. Prelim. Resp. 1, 5–11, citing Ex.
`1028 (“Findings of Fact and Conclusions of Law Following Bench Trial
`August 19, 2013”). Patent Owner contends that the prior district court
`decision currently is pending before the Federal Circuit and will precede any
`ruling by the Board. Id. at 11–12. Patent Owner argues that the upcoming
`Federal Circuit decision will be dispositive of the issues raised by Petitioner.
`Id. at 12–17.
`
`We have considered Patent Owner’s contentions but do not find them
`persuasive on this record. Patent Owner does not contend that Petitioner is
`barred from raising its specific challenges before this tribunal. Also, the
`district court decision did not address the patentability of claims 1–8, 11, 13,
`16, 17, 20, and 22. Ex. 1028. Further, the district court’s analysis focused
`on “Worzalla and Hammond as prior art” and “’974 Patent as prior art,” and
`relied heavily on the testimony of Patent Owner’s experts, Drs. Chabner and
`Zeisel. Ex. 1028, 10–16. In contrast, the challenge raised in this proceeding
`focuses on the Rusthoven reference in combination with EP 005, where the
`testimonial evidence presented is distinct from that in the district court. Pet.
`25–51. Specifically, Petitioner’s expert, Dr. Bleyer, does not appear to have
`testified in the district court proceeding, and Patent Owner has not submitted
`testimony in this proceeding from Drs. Chabner and Zeisel.
`
`Based upon the facts presented, we are not persuaded that the decision
`by the Federal Circuit will dispose of the issues raised in the Petition. In re
`Swanson, 540 F.3d 1368, 1377 (Fed. Cir. 2008) (A finding that a patent is
`
`9
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`valid operates only on the parties and does not extend from one case to the
`next. A future challenger with new or better information may subsequently
`raise, and succeed on invalidity).
`
`
`III. MERITS ANALYSIS
`
`A.
`Claim Interpretation
`In an inter partes review, the Board interprets claim terms in an
`
`unexpired patent according to the broadest reasonable construction in light
`of the specification of the patent in which they appear. 37 C.F.R. § 100(b).
`Under that standard, and absent any special definitions, we give claim terms
`their ordinary and customary meaning, as would be understood by one of
`ordinary skill in the art at the time of the invention. In re Translogic Tech.,
`Inc., 504 F.3d 1249, 1257 (Fed. Cir. 2007). Any special definitions for
`claim terms must be set forth with reasonable clarity, deliberateness, and
`precision. In re Paulsen, 30 F.3d 1475, 1480 (Fed. Cir. 1994).
`Petitioner identifies several claim terms in the challenged claims and
`provides definitions for those terms. Pet. 12–15. Patent Owner does not
`take a position on claim construction at this time.
`We determine that it is unnecessary to construe explicitly the claim
`terms for purposes of this Decision. See Wellman, Inc. v. Eastman Chem.
`Co., 642 F.3d 1355, 1361 (Fed. Cir. 2011) (“[C]laim terms need only be
`construed ‘to the extent necessary to resolve the controversy.’”) (quoting
`Vivid Techs., Inc. v. Am. Sci. & Eng’g, Inc., 200 F.3d 795, 803 (Fed. Cir.
`1999)).
`
`Section 103 Obviousness Challenge
`B.
`Petitioner raises one challenge based on 35 U.S.C. § 103. Generally,
`
`10
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`Petitioner contends that the challenged claims merely require administering
`a specific antifolate cancer drug, which was known to elevate a patient’s
`homocysteine levels, with compounds known to decrease homocysteine
`levels, folic acid and vitamin B12. Pet. 16–21. Based on the current record,
`we determine that Petitioner has established a reasonable likelihood that it
`would prevail in showing claims 1–22 are unpatentable as obvious over the
`cited art.
`
`
`1. Background on Obviousness
`An invention is not patentable under 35 U.S.C. § 103 if it is obvious.
`KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 427 (2007). Under § 103:
`the scope and content of the prior art are to be determined;
`differences between the prior art and the claims at issue are to
`be ascertained; and the level of ordinary skill in the pertinent art
`resolved. Against this background, the obviousness or
`nonobviousness of the subject matter is determined.
`
`Graham v. John Deere Co., 383 U.S. 1, 17 (1966). In addressing the
`findings of fact, “[t]he combination of familiar elements according to known
`methods is likely to be obvious when it does no more than yield predictable
`results.” KSR, 550 U.S. at 416. As explained in KSR:
`If a person of ordinary skill can implement a predictable
`variation, § 103 likely bars its patentability. For the same
`reason, if a technique has been used to improve one device, and
`a person of ordinary skill in the art would recognize that it
`would improve similar devices in the same way, using the
`technique is obvious unless its actual application is beyond his
`or her skill.
`
`
`
`
`
`
`11
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`Id. at 417. Accordingly, a central question in analyzing obviousness is
`“whether the improvement is more than the predictable use of prior art
`elements according to their established functions.” Id.
`
`
`2. The Prior Art References
`a. Rusthoven (Ex. 1011)
`
`Rusthoven describes a phase II study evaluating the efficacy and
`safety of multitargeted antifolate LY231514 (“MTA”) in patients receiving
`initial chemotherapy for advanced non-small-cell lung cancer (“NSCLC”).
`Ex. 1011, 1194. The study involved thirty-three patients, all of whom were
`assessed for toxicity. Id. Initial MTA dosages were reduced after three
`patients received MTA treatment because of toxicity seen in the study and
`another Canadian MTA trial in colorectal cancer. Id. Rusthoven states that
`earlier MTA studies suggested that “dietary supplementation with folic acid
`may improve the therapeutic index by reducing toxicity in mice.” Id. at
`1195.
`
`Based on the results of the study, Rusthoven reported that MTA seems
`to have exhibited a clinically meaningful activity against NSCLC and
`toxicity was said to be “generally mild and tolerable,” although ten of the
`thirty-three patients dropped protocol therapy due to toxicity. Id. at 1194.
`Rusthoven states that their group is conducting a phase II study of MTA in
`combination with cisplatin drugs for NSCLC. Id. at 1198.
`
`
`b. EP 005 (Ex. 1010)
`
`EP 005 describes pharmaceutical preparations for lowering blood and
`tissue levels of homocysteine and counteracting harmful effects associated
`
`12
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`with homocysteine. Ex. 1010, 2:1–3. Elevated homocysteine levels are
`highly undesirable and normalization of elevated levels constitutes a
`therapeutic goal. Id. at 3:7–9.
`Three pathways are said to exist to control homocysteine including
`remethylation to methionine, which requires folate and vitamin B12 as a
`co-factor. Id. at 2:25–30. EP 005 identifies a number of publications that
`are said to describe the relationship between B12 and folate levels
`individually and blood levels of homocysteine. Id. at 3:37–45. EP 005
`seeks to lower total homocysteine blood levels elevated by any known
`cause, including drugs that induce elevated homocysteine levels, such as
`methotrexate, a well-known antifolate. Id. at 4:43–48.
`EP 005 discloses a pharmaceutical preparation comprising vitamin
`B6, folate and vitamin B12, for prophylaxis or treatment of elevated levels
`of homocysteine in a patient. Id. at 4:37–42. According to EP 005, for
`purposes of controlling blood homocysteine levels, the combination of
`folate, vitamin B12 and B6 produces advantageous effects and provides an
`unexpected synergism that goes substantially beyond what would be
`expected from a simple additive effect of the action of these compounds. Id.
`at 11:20–25. A suitable daily dosage of the pharmaceutical preparation is
`described as:
`
`13
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`
`
`
`
`Id. at 8:14–51. As represented in the chart above, PL (pyridoxal) is the
`preferred form of vitamin B6. Id. at 6:12–17.
`
`
`c. Calvert 1999 (Ex. 1014)
`
`As background regarding what an ordinary artisan would have known
`when reading the prior art references discussed above, Petitioner points to
`Calvert 1999. Pet. 15–17. Calvert 1999 provides an overview of folate
`metabolism and describes features relevant to the action and toxicities of
`antifolate cancer agents. Ex. 1014, 3. According to Calvert 1999, the
`development of cancer therapeutics has been linked intimately to the study
`of folic acid metabolism and the action of antifolate drugs. Id. Calvert 1999
`depicts the chemical structures of various antifolates, including
`methotrexate, lometrexol and MTA. Id. at 6. Folic acid supplementation is
`said to reduce the toxicity of antifolate drugs. Id. at 8. Calvert 1999 also
`discusses, however, how it had been difficult to correlate antifolate-induced
`toxicity with pretreatment folate levels. Id.
`
`14
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`Calvert 1999 teaches that intracellular homocysteine can be reduced
`by converting it to methionine through remethylation by methionine
`synthase. Id. at 8–9. As depicted below, methionine synthase requires
`folate (5-methyltetrahydrofolate) as a methyl donor and vitamin B12 as a
`cofactor for the remethylation reaction:
`
`
`
`
`
`Id. at 9. Calvert 1999 states that an increase in the plasma level of
`homocysteine occurs when there is a functional deficiency in either B12 or
`folate. Id.
`
`
`3. Independent Claims 1 and 12
`
`Generally, Petitioner contends that it was well known in the art
`
`that antifolates, such as MTA, had anticancer properties, and that it
`was known that toxicity had limited the administration of antifolates,
`such as methotrexate and MTA. Pet. 16–17. Petitioner states that it
`was known in the art that MTA had activity in a variety of tumors and
`that elevated levels of homocysteine were observed in patients treated
`with antifolates, such as MTA. Id. at 17, citing Calvert 1999, 8–9.
`Petitioner explains that it was known in the art that homocysteine
`
`15
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`could be reduced by two pathways, including remethylation by
`methionine synthase, which requires folate as a methyl donor and
`vitamin B12 as a cofactor for the remethylation reaction. Id. at 17–19.
`Additionally, Petitioner states that one skilled in the art would
`understand from Rusthoven it was desirable to treat patients with
`MTA and that administering an effective amount of folic acid would
`reduce a patient’s MTA toxicity. Id. at 25.
`
`Petitioner states that EP 005 teaches that one skilled in the art
`can control drug-induced homocysteine levels, including antifolate
`drug induced levels, by pretreatment with a combination of folic acid,
`vitamin B12 and vitamin B6. Id. at 22–23, 27–29 and 33–39.
`Petitioner relies upon the testimony of Dr. Bleyer to support its
`contention that pretreating an MTA patient with folic acid and vitamin
`B12 was suggested by the prior art, which recognized the benefit of
`the combination of folic acid and vitamin B12 for controlling
`homocysteine levels in antifolate patients. Pet. 15–39, Ex. 1024.
`Further, Petitioner relies upon EP 005 for its teaching that 1000 mg of
`folic acid and 500 mg of vitamin B12 are preferred daily dosage
`amounts. Id. at 42–43; Ex. 1024 ¶¶ 136–139. As noted above, Patent
`Owner chose not to address the merits of the Petition in its
`Preliminary Response. Paper 10, 1 n.1.
`Based upon the record presented, we credit Dr. Bleyer’s
`testimony as follows. On this record, we find that Rusthoven
`demonstrates that MTA was a known antifolate cancer treatment
`agent. Ex. 1024 ¶¶ 98–99. We also find that that Rusthoven teaches
`one skilled in the art at the time of the invention that it was recognized
`that folic acid treatment may reduce the patient toxicity when
`
`16
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`administering MTA. Id. at ¶¶ 107, 121. On this record, we find that
`EP 005 would have led one of ordinary skill in the art to understand
`that pretreatment with folic acid and vitamin B12 would stimulate
`recycling of methionine in the body and control homocysteine levels.
`Id. ¶¶ 100–102. We credit Dr. Bleyer’s testimony, as it is consistent
`with the references of record.
`Based upon the record presented, we conclude that Petitioner
`has shown a reasonable likelihood of prevailing in its assertion that
`independent claims 1 and 12 are unpatentable over Rusthoven and
`EP 005. Specifically, Petitioner has established sufficiently that
`administering folic acid and vitamin B12 followed by the
`administration of MTA to a patient in need represents a combination
`of known treatments, used for their known purpose (treating cancer
`patients, controlling homocysteine levels) to achieve a predictable
`result (controlling homocysteine levels in a cancer patient). Id. ¶ 148.
`
`
`4. Dependent Claims 2–11, 13–22
`
`
`
`
`
`Dependent claims 2–11 and 13–22 generally recite various
`dosages of folic acid and B12, as well as times for administering folic
`acid. Certain dependent claims require the administration of cisplatin
`to the patient. For example, dependent claim 13 further requires the
`administration of cisplatin, and dependent claim 14 requires vitamin
`B12 be administered as an intramuscular injection of about 500 μg to
`about 1500 μg.
`Petitioner contends that the dependent claims merely add
`limitations already known in the field and would have been obvious to
`
`17
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`one of ordinary skill in the art. Pet. 37–48. According to Petitioner, it
`would have been obvious to administer the specific dosage amounts
`recited in the claims, as EP 005 discloses amounts falling within the
`claimed range as effective amounts to control homocysteine levels.
`Id. at 39–45. Petitioner also relies upon EP 005 for its teaching that
`vitamin B12 and folic acid may be administered via intramuscular
`injection. Id. at 22, 36–37, 39.
`As to the timing of the dosages, Petitioner contends that EP
`005 teaches that its pharmaceutical preparations are made available on
`a timed program dosage regime, which provides for different dosages
`during different periods over the course of treatment and one skilled
`in the art would have adjusted the program to the clinical condition of
`the patient. Id. at 40–41; Ex. 1024 ¶ 145. Petitioner further states that
`one skilled in the art would have recognized the benefit of
`administering cisplatin with MTA, as Rusthoven discloses studies
`with MTA and cisplatin administration. Pet. 45–48; Ex. 1024 ¶¶ 152,
`154. Petitioner’s contentions are supported by the declaration of Dr.
`Bleyer, whose testimony on this record is consistent with the
`teachings of the cited references. As mentioned above, Patent Owner
`chose not to address the merits of the Petition in its Preliminary
`Response. Paper 9, 1 n.1.
`Based on the record presented, Petitioner has shown a
`reasonable likelihood of prevailing in its assertion that dependent
`claims 2–11 and 13–22 are unpatentable over Rusthoven and EP 005.
`Specifically, Petitioner has established sufficiently that administering
`folic acid and vitamin B12 in the specified ranges followed by the
`administration of MTA, alone or with cisplatin, to a patient in need
`
`18
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`represents a combination of known treatments using known ranges,
`used for their known purpose (treating cancer patients, controlling
`homocysteine levels) to achieve a predictable result (controlling
`homocysteine levels in a cancer patient). Ex. 1024 ¶¶ 139–155.
`
`IV. CONCLUSION
`For the foregoing reasons, we determine that the information
`presented in the Petition, notwithstanding the Preliminary Response,
`establishes that there is a reasonable likelihood that Petitioner would prevail
`in demonstrating unpatentability of claims 1–22. The Board has not yet
`made a final determination of the patentability of any of claims 1–22 of the
`’209 patent.
`
`V. ORDER
`Accordingly, it is
`ORDERED that pursuant to 35 U.S.C. § 314, an inter partes review is
`hereby instituted as to claims 1–22 of the ’209 patent on the following
`ground:
`References
`
`Claims challenged
`
`Basis
`
`1–22
`
`§ 103
`
`Rusthoven in view of EP 005
`
`FURTHER ORDERED that pursuant to 35 U.S.C. § 314(c) and 37
`
`C.F.R. § 42.4, notice is hereby given of the institution of a trial commencing
`on the entry date of this decision.
`
`
`
`
`19
`
`
`
`IPR2016-00240
`Patent 7,772,209 B2
`PETITIONER:
`
`Sarah Spires
`Parvathi Kota
`Skiermont Derby LLP
`240neptune@skiermontderby.com
`
`PATENT OWNER:
`
`Dov Grossman
`David Krinsky
`Williams & Connolly LLP
`dgrossman@wc.com
`dkrinsky@wc.com
`
`James Leeds
`Eli Lilly & Company
`leeds_james@lilly.com
`
`
`
`
`20
`
`